EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 444 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... August 14, 2025 Beauty, Healing and Space January 27, 2021 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... March 26, 2025 Load more HOT NEWS The long road to targeting the holy grail of the immune... Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... Determination of the Incidence of Driver Mutations in Patients with NSCLC...
